3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Colorectal Neoplasms
57
Carcinoma, Non-Small-Cell Lung
29
Breast Neoplasms
18
Rectal Neoplasms
14
Ovarian Neoplasms
14
Carcinoma, Hepatocellular
10
Neoplasm Metastasis
9
Glioblastoma
9
Colonic Neoplasms
9
Carcinoma, Renal Cell
8
Uterine Cervical Neoplasms
7
Fallopian Tube Neoplasms
7
Brain Neoplasms
6
Neoplasms
5
Nasopharyngeal Carcinoma
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Liver Neoplasms
4
Inflammatory Breast Neoplasms
4
Colorectal Cancer Metastatic
4
Carcinoma, Ovarian Epithelial
4
Stomach Neoplasms
3
Pleural Effusion, Malignant
3
Meningeal Carcinomatosis
3
Melanoma
3
Kidney Neoplasms
3
Glioma
3
Non-squamous Non-small Cell Lung Cancer
2
Liver Metastasis Colon Cancer
2
Interventions
Musculoskeletal Manipulations
2
niraparib
1
adrenosterone
1
Ultrasonography
1
Hematologic Tests
1
Diffusion
1
Dehydroepiandrosterone
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Endocrine System Diseases
×
Bevacizumab
×
Clear all
NCT04556071
2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
32 enrolled